Navigation Links
Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets
Date:8/21/2014

AUSTIN, Texas, Aug. 21, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, has appointed Holly B. Bauzon as Vice President of Sales and Managed Markets.

Ms. Bauzon has a proven track record in both increasing sales traction and expanding payer coverage for laboratory services companies. She has more than 20 years of healthcare experience, most recently with PerkinElmer, Inc., where she held the position of Director, Lab Services Sales and Managed Markets.

"We are excited to bring Holly's skills and experience to bear on our stated goals of accelerating the adoption of OVA1 and expanding our payer base", said James LaFrance, Vermillion's Chairman, President and Chief Executive Officer. "Holly did just that with PerkinElmer where she grew prenatal revenue and established 280 new contracts with payers – including key national payers."

Prior to her seven year tenure at PerkinElmer, Ms. Bauzon held commercial management and payer relations positions at PolyMedica Corporation, National Diabetic Pharmacies, Inc. and Byram Healthcare, Inc. Ms. Bauzon has a Bachelor of Science degree in Health Science from East Stroudsburg University.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

About ASPiRA LABS
ASPiRA LABS is an innovative diagnostic services laboratory founded by Vermillion, Inc., a leader in women's health diagnostics. The laboratory's goal is to provide high quality, innovative testing for women to help address unmet women's health needs. ASPiRA LABS' specialized services are grounded in evidence-based medicine, while providing access to novel biomarker diagnostic tools designed to help health care professionals offer the most precise diagnoses and treatment guidance for their patients. To learn more about ASPiRA LABS, visit www.aspiralab.com.

Investor Relations Contact:
Eric Schoen
Vice President, Finance and Chief Accounting Officer
Tel 512-519-0424
eschoen@vermillion.com


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Reports Second Quarter 2014 Results
2. Vermillion Announces Additions to Commercial Management Team
3. Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014
4. Vermillion Completes $17.6 Million Warrant Exercise
5. Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
6. Vermillion Reports Third Quarter 2013 Results
7. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
8. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
9. Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
10. Vermillion Appoints Dr. Eric Varma to its Board of Directors
11. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by patients ... having low level of oxygen in their blood ... are to be used only with prescription and ... concentrators work either on rechargeable lithium batteries or ...
(Date:2/21/2017)...   BeyondSpring Pharmaceuticals , a clinical stage ... immuno-oncology cancer therapies, today announced that the Company,s ... 2 trial of BeyondSpring,s innovative lead asset, ... lung cancer (NSCLC) with Docetaxel has been selected ... Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
(Date:2/21/2017)... NJ (PRWEB) , ... February 21, 2017 , ... ... research and conference coverage in veterinary medicine, will be launching its first bi-monthly ... animal health and medicine, business and practice management, and One Health. , ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):